Aldeyra Therapeutics Inc. (ALDX) to Release Quarterly Earnings on Monday
Aldeyra Therapeutics Inc. (NASDAQ:ALDX) will announce its Q316 earnings results before the market opens on Monday, November 14th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter.
Shares of Aldeyra Therapeutics Inc. (NASDAQ:ALDX) opened at 6.35 on Friday. The stock’s market cap is $79.20 billion. The firm has a 50-day moving average price of $6.69 and a 200-day moving average price of $6.04. Aldeyra Therapeutics Inc. has a one year low of $3.39 and a one year high of $8.19.
A number of equities analysts have commented on the stock. Zacks Investment Research upgraded shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a report on Tuesday, October 25th. HC Wainwright assumed coverage on shares of Aldeyra Therapeutics in a report on Monday, September 26th. They issued a “buy” rating and a $18.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, Aldeyra Therapeutics presently has a consensus rating of “Buy” and an average price target of $14.42.
Large investors have recently modified their holdings of the stock. Northern Trust Corp raised its stake in shares of Aldeyra Therapeutics by 3.9% in the third quarter. Northern Trust Corp now owns 12,846 shares of the biotechnology company’s stock worth $100,000 after buying an additional 480 shares during the period. BlackRock Fund Advisors raised its stake in Aldeyra Therapeutics by 1,944.6% in the second quarter. BlackRock Fund Advisors now owns 20,630 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 19,621 shares during the period. Vanguard Group Inc. raised its stake in Aldeyra Therapeutics by 3.1% in the second quarter. Vanguard Group Inc. now owns 125,125 shares of the biotechnology company’s stock valued at $712,000 after buying an additional 3,718 shares during the period. FMR LLC raised its stake in Aldeyra Therapeutics by 25.0% in the second quarter. FMR LLC now owns 1,797,811 shares of the biotechnology company’s stock valued at $10,230,000 after buying an additional 360,000 shares during the period. Finally, Perceptive Advisors LLC raised its stake in Aldeyra Therapeutics by 56.4% in the second quarter. Perceptive Advisors LLC now owns 1,940,458 shares of the biotechnology company’s stock valued at $11,041,000 after buying an additional 700,000 shares during the period. Institutional investors and hedge funds own 50.99% of the company’s stock.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Stock Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related stocks with our FREE daily email newsletter.